Ayuob Aghanejad

Dr. Ayuob Aghanejad

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
JKJamileh Kadkhoda
Jamileh Kadkhoda
ATAli Tarighatnia
Ali Tarighatnia
JBJaleh Barar
Jaleh Barar
AAAyuob Aghanejad
Ayuob Aghanejad
SDSoodabeh Davaran
Soodabeh Davaran

1 April 2021 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
BSBanafsheh Safari
Banafsheh Safari
SDSoodabeh Davaran
Soodabeh Davaran
AAAyuob Aghanejad
Ayuob Aghanejad

30 March 2016 in BioImpacts
Verified
Journal Article
Open access
JBJaleh Barar
Jaleh Barar
AAAyuob Aghanejad
Ayuob Aghanejad
MFMarziyeh Fathi
Marziyeh Fathi
YOYadollah Omidi
Yadollah Omidi
Ocular targeted therapy has enormously been advanced by implementation of new methods of drug delivery and targeting using implantable drug delivery systems (DDSs) or devices (DDDs), stimuli-responsive advanced biomaterials, multimodal nanomedicines, cell therapy modalities and medical bioMEMs. These technologies tackle several ocular diseases such as inflammation-based diseases (e.g., scleritis, keratitis, uveitis, iritis, conjunctivitis, chorioretinitis, choroiditis, retinitis, retinochoroiditis), ocular hypertension and neuropathy, age-related macular degeneration and mucopolysaccharidosis (MPS) due to accumulation of glycosaminoglycans (GAGs). Such therapies appear to provide ultimate treatments, even though much more effective, yet biocompatible, noninvasive therapies are needed to control some disabling ocular diseases/disorders. In the current study, we have reviewed and discussed recent advancements on ocular targeted therapies. On the ground that the pharmacokinetic and pharmacodynamic analyses of ophthalmic drugs need special techniques, most of ocular DDSs/devices developments have been designed to localized therapy within the eye. Application of advanced DDSs such as Subconjunctival insert/implants (e.g., latanoprost implant, Gamunex-C), episcleral implant (e.g., LX201), cationic emulsions (e.g., Cationorm™, Vekacia™, Cyclokat™), intac/punctal plug DDSs (latanoprost punctal plug delivery system, L-PPDS), and intravitreal implants (I-vitaion™, NT-501, NT- 503, MicroPump, Thethadur, IB-20089 Verisome™, Cortiject, DE-102, Retisert™, Iluvein™ and Ozurdex™) have significantly improved the treatment of ocular diseases. However, most of these DDSs/devices are applied invasively and even need surgical procedures. Of these, use of de novo technologies such as advanced stimuli-responsive nanomaterials, multimodal nanosystems (NSs)/nanoconjugates (NCs), biomacromolecualr scaffolds, and bioengineered cell therapies need to be further advanced to get better compliance and higher clinical impacts. Despite mankind successful battle on ocular diseases, our challenge will continue to battle the ocular disease that happen with aging. Yet, we need to understand the molecular aspects of eye diseases in a holistic way and develop ultimate treatment protocols preferably as non-invasive systems.

10 April 2017 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
ZBZahra Bakhtiary
Zahra Bakhtiary
JBJaleh Barar
Jaleh Barar
AAAyuob Aghanejad
Ayuob Aghanejad
Amirata Saei DibavarAmirata Saei Dibavar
Amirata Saei Dibavar
ENElhameh Nemati
Elhameh Nemati
YOYadollah Omidi
Yadollah Omidi
Non-small cell lung cancer (NSCLC) patients with sensitizing mutations in the exons 18–21 of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR. Hence, tyrosine kinase inhibitors (TKIs) such as erlotinib (ETB) have commonly been used as the second line therapeutic option for the treatment of metastatic NSCLC. While the ETB is available as an oral dosage form, the local delivery of this TKI to the diseased cells of the lung may ameliorate its therapeutic impacts. In the current study, we report on the development of ETB-loaded solid lipid nanoparticle (SLN) based formulation of dry powder inhaler (ETB-SLN DPI). ETB-SLNs were formulated using designated amount of compritol/poloxamer 407. The engineered ETB-SLNs showed sub-100 nm spherical shape with an encapsulation efficiency of 78.21%. MTT assay and DAPI staining revealed that the ETB-SLNs enhanced the cytotoxicity of cargo drug molecules in the human alveolar adenocarcinoma epithelial A549 cells as a model for NSCLC. To attain the ETB-SLN DPI, the ETB-SLNs were efficiently spray dried into microparticles (1–5 μm) along with mannitol. The ETB-SLN DPI powder displayed suitable flowability and aerodynamic traits. The Carr's Index, Hausner ratio and Next Generation Impactor (NGI) analyses confirmed deep inhalation pattern of the formulation. Based on these findings, we propose the ETB-SLN DPI as a promising treatment modality for the NSCLC patients.

1 September 2020 in Ageing Research Reviews
Verified
Journal Article
Closed access
AAAmir Ajoolabady
Amir Ajoolabady
HAHamid Aslkhodapasandhokmabad
Hamid Aslkhodapasandhokmabad
AAAyuob Aghanejad
Ayuob Aghanejad
YZYingmei Zhang
Yingmei Zhang
JRJun Ren
Jun Ren

1 February 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
BSBanafsheh Safari
Banafsheh Safari
AAAyuob Aghanejad
Ayuob Aghanejad
LRLeila Roshangar
Leila Roshangar
SDSoodabeh Davaran
Soodabeh Davaran